Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1

Interventions

Specimen Handling 631pembrolizumab 610Magnetic Resonance Spectroscopy 553Carboplatin 450Cisplatin 398Cyclophosphamide 397Biopsy 375Nivolumab 326Paclitaxel 324Gemcitabine 317Radiotherapy 286Bevacizumab 244Dexamethasone 222fludarabine 215Docetaxel 199durvalumab 195venetoclax 188Oxaliplatin 187atezolizumab 184Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 169Radiation 167Doxorubicin 166Radiosurgery 159Ipilimumab 147Etoposide 142Leucovorin 141Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sra protein, Drosophila × 90 days × Clear all
NCT07464210 2026-03-11

Nemtabrutinib, Bortezomib, and Rituximab for WM

Seoul National University Hospital

Phase 2 Not yet recruiting
19 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡